Medicenna Therapeutics Corp (MDNAF)

$1.01 +0.04 (3.98%)
Market Cap 80.91M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 99,900
Avg Vol 78,118
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 27%
Beta 1.72
Analysts Strong Sell
Price Target $4.03

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
_Osmium
_Osmium Nov. 15 at 8:22 PM
$MDNAF Merck just purchased Cidara for $9B. This appears to offset revenue lost due to the approaching Keytruda patent cliff. Why mention this here? Merck was one of the prominent companies who could make a deal with Medicenna to bolster its Keytruda drug. David's Substack had mentioned this too. By my queries I have AstraZeneca, GlaxoSmithKline and Pfizer remaining as companies most interested, most capitalized in acquiring next generation IL-2. I feel Pfizer is more likely even though they too have made a very recent large purchase of $7B for Metsera. Lots of money is being thrown around by big pharma. Are they done spending? Who knows but how about a smallish licensing deal: $50 M upfront etcetera. This really isn't too much to ask especially if Medicenna's beta approach to repriming the immune system proves correct. Few more weeks to find out. Can't believe I'm writing this on a Saturday. Best of luck.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 13 at 1:17 PM
$MDNAF MD&A https://ceo.ca/content/sedar/MDNA-2025-11-12-interim-mda-english-c352.pdf
0 · Reply
Spartrap
Spartrap Nov. 13 at 12:19 PM
$MDNAF «"We are e͟a͟g͟e͟r͟l͟y͟ a͟n͟t͟i͟c͟i͟p͟a͟t͟i͟n͟g͟ the upcoming clinical update for MDNA11 from the global phase 1/2 ABILITY-1 clinical trial to demonstrate its potential as a best-in-class IL-2 therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna» (stress mine) At least he doesn't seem too concerned about making dicey forward looking statements. I like the confidence.
1 · Reply
Lytnup
Lytnup Nov. 13 at 4:31 AM
$MDNAF Here’s to tomorrow’s filings….. https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-part-8?r=10wt7d&utm_medium=ios
0 · Reply
Lytnup
Lytnup Nov. 12 at 1:12 PM
$MDNAF While we wait for December…… https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-episode-6?r=10wt7d&utm_medium=ios https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-part-7?r=10wt7d&utm_medium=ios
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 11 at 9:47 PM
$MDNAF Shame…There will be no run up to news with the announcement of this two-bit webinar, guaranteed.
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 11 at 9:39 PM
$MDNAF Who would bother with this if you got bank??? The zoom isn’t even with PennyQueen at least she has 7K+ followers…(and she’s hot)!
0 · Reply
_Osmium
_Osmium Nov. 11 at 5:58 PM
$MDNAF Definitely not a fan of the Zoom webinar. He has been to 3 recent conferences supposedly getting the word out and decides a webinar is still needed. He won't say anything that he hasn't in the past webinars but will certainly mention the recent buyout as a comparator. He's behaved like that since the buyouts of 2019! Aside from David's Substack relentlessly singing the praises of MDNA11, no one else is even remotely interested. The pull back today on the stock appears like a vote against this low-level webinar approach too. (Maybe they salvage the price above $1 in the afternoon.) It's tiring and frustrating for all shareholders. In 29 days, we'll have an answer. The optimist in me says it will be the right answer; I'll leave the pessimist in me to just ruminate several more weeks.
2 · Reply
Spartrap
Spartrap Nov. 10 at 8:55 PM
$MDNAF looks like X:@RNA_biotech has gone crazy bullish. If only he could be right.. Also, a zoom webinar is now programmed with X:@RadiusResearch, Nov 18th
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 10 at 3:47 PM
$MDNAF oh ya 250P - ABILITY-1, a phase 1/2 study of MDNA11, a next generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors: interim analysis André Mansinho, HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, Portugal
0 · Reply
Latest News on MDNAF
No data available.
_Osmium
_Osmium Nov. 15 at 8:22 PM
$MDNAF Merck just purchased Cidara for $9B. This appears to offset revenue lost due to the approaching Keytruda patent cliff. Why mention this here? Merck was one of the prominent companies who could make a deal with Medicenna to bolster its Keytruda drug. David's Substack had mentioned this too. By my queries I have AstraZeneca, GlaxoSmithKline and Pfizer remaining as companies most interested, most capitalized in acquiring next generation IL-2. I feel Pfizer is more likely even though they too have made a very recent large purchase of $7B for Metsera. Lots of money is being thrown around by big pharma. Are they done spending? Who knows but how about a smallish licensing deal: $50 M upfront etcetera. This really isn't too much to ask especially if Medicenna's beta approach to repriming the immune system proves correct. Few more weeks to find out. Can't believe I'm writing this on a Saturday. Best of luck.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 13 at 1:17 PM
$MDNAF MD&A https://ceo.ca/content/sedar/MDNA-2025-11-12-interim-mda-english-c352.pdf
0 · Reply
Spartrap
Spartrap Nov. 13 at 12:19 PM
$MDNAF «"We are e͟a͟g͟e͟r͟l͟y͟ a͟n͟t͟i͟c͟i͟p͟a͟t͟i͟n͟g͟ the upcoming clinical update for MDNA11 from the global phase 1/2 ABILITY-1 clinical trial to demonstrate its potential as a best-in-class IL-2 therapy,” said Fahar Merchant, Ph.D., President and CEO of Medicenna» (stress mine) At least he doesn't seem too concerned about making dicey forward looking statements. I like the confidence.
1 · Reply
Lytnup
Lytnup Nov. 13 at 4:31 AM
$MDNAF Here’s to tomorrow’s filings….. https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-part-8?r=10wt7d&utm_medium=ios
0 · Reply
Lytnup
Lytnup Nov. 12 at 1:12 PM
$MDNAF While we wait for December…… https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-episode-6?r=10wt7d&utm_medium=ios https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-part-7?r=10wt7d&utm_medium=ios
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 11 at 9:47 PM
$MDNAF Shame…There will be no run up to news with the announcement of this two-bit webinar, guaranteed.
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 11 at 9:39 PM
$MDNAF Who would bother with this if you got bank??? The zoom isn’t even with PennyQueen at least she has 7K+ followers…(and she’s hot)!
0 · Reply
_Osmium
_Osmium Nov. 11 at 5:58 PM
$MDNAF Definitely not a fan of the Zoom webinar. He has been to 3 recent conferences supposedly getting the word out and decides a webinar is still needed. He won't say anything that he hasn't in the past webinars but will certainly mention the recent buyout as a comparator. He's behaved like that since the buyouts of 2019! Aside from David's Substack relentlessly singing the praises of MDNA11, no one else is even remotely interested. The pull back today on the stock appears like a vote against this low-level webinar approach too. (Maybe they salvage the price above $1 in the afternoon.) It's tiring and frustrating for all shareholders. In 29 days, we'll have an answer. The optimist in me says it will be the right answer; I'll leave the pessimist in me to just ruminate several more weeks.
2 · Reply
Spartrap
Spartrap Nov. 10 at 8:55 PM
$MDNAF looks like X:@RNA_biotech has gone crazy bullish. If only he could be right.. Also, a zoom webinar is now programmed with X:@RadiusResearch, Nov 18th
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 10 at 3:47 PM
$MDNAF oh ya 250P - ABILITY-1, a phase 1/2 study of MDNA11, a next generation IL-2 agonist, alone or with pembrolizumab in advanced solid tumors: interim analysis André Mansinho, HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, Portugal
0 · Reply
ablor
ablor Nov. 10 at 3:41 PM
$MDNAF So did they get a paper in for ESMO or not?
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 10 at 3:12 PM
$MDNAF Any guesses on the timing of the primate data for MDNA113?
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 10 at 2:16 PM
$MDNAF Let’s goooooooo!
0 · Reply
rudazur2
rudazur2 Nov. 10 at 10:23 AM
$MDNAF 1 month
0 · Reply
AuriniaBeach
AuriniaBeach Nov. 9 at 3:47 PM
$MDNAF MDNA11 For Dummies, Episode 5 ““Why It’s Beating the Odds (When So Many Others Fail)” Let’s be honest — cancer drugs fail a lot. Not because the science is bad, but because tumors are smarter than we ever gave them credit for. They build walls, cut power lines, and jam the immune system’s signal before help ever arrives. That’s why MDNA11 is different. It wasn’t built to smash through the tumor. It was built to reconnect the immune system to it.” https://davidbakke.substack.com/p/mdna11-for-dummies-episode-5
1 · Reply
Lytnup
Lytnup Nov. 9 at 3:45 PM
$MDNAF And…..#5. https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-episode-5?r=10wt7d&utm_medium=ios
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 8 at 5:58 PM
$MDNAF might be a bit sooner!!… All regular abstracts accepted for presentation at the ESMO Immuno-Oncology Congress 2025 as Proffered Paper (suffix O), Mini Oral (suffix MO), Poster (suffix P or TiP), ePoster (suffix eP or eTiP) will be published online via the ESMO website at 00.05 CET on Thursday, 4 December 2025.
0 · Reply
Lytnup
Lytnup Nov. 8 at 2:25 PM
$MDNAF More light reading for the weekend https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-episode-4?r=10wt7d&utm_medium=ios Less than 6 weeks to ESMO Immuno - Oncology in London, Dec 10 - 12. https://www.esmo.org
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 7 at 5:14 PM
$MDNAF or maybe not ha
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Nov. 7 at 4:47 PM
$MDNAF let’s see some Friday action here! Soon the last chance for a deal !
0 · Reply
Lytnup
Lytnup Nov. 7 at 3:28 PM
$MDNAF For those with interest, I have found David’s set of write ups about MDNA11 to be helpful in understanding the science a little bit better, and am looking forward to seeing more data next month. https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-episode-1?r=10wt7d&utm_medium=ios https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-episode-2?r=10wt7d&utm_medium=ios https://open.substack.com/pub/davidbakke/p/mdna11-for-dummies-episode-3?r=10wt7d&utm_medium=ios
0 · Reply
Notorious_Johnny_V
Notorious_Johnny_V Nov. 7 at 2:28 AM
$MDNAF From today's news release... "MDNA11 was designed to selectively awaken the immune system’s cancer fighting immune cells without fanning the flames of suppression. We’ve already seen deep durable responses with MDNA11 in heavily pretreated patients with advanced metastatic cancers and profoundly compromised immune systems in the on-going ABILITY-1 trial". I sense a bit of optimism. Sounds like upcoming results will be pretty good. Fingers crossed 🤞🏽
0 · Reply